Zafgen Inc., after going through setbacks last year including patient deaths, has something to cheer on. The obesity-focused biopharmaceutical company’s trial for Beloranib, intended to treat severe obesity complicated by type 2 diabetes, showed statistically and clinically significant improvements in body weight, body composition, and glycemic control.